Solara Active Pharma Sciences Ltd Financials
Company Logo

Solara Active Pharma Sciences Ltd Financial Statement

Solara Active Pharma Sciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue347.27
Operating Expense285.63
Net Profit8.02
Net Profit Margin2.31
Earning Per Share2.11
EBIDTA61.64
Effective Tax RateTBA

Solara Active Pharma Sciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual1,288.92
Operating Expenses Annual1,383.98
Operating Profit Annual-279.33
Interest Annual105.97
Depreciation88.21
Net Profit Annual-566.87
Tax Annual78.54

Solara Active Pharma Sciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning8.55
Cash Flow from Operations110.95
Cash Flow from Investing-4.66
Cash Flow from Financing-106.52
Cash Flow at the End8.32

Solara Active Pharma Sciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)-6.99
PBIT Margin (%)-14.98
PBT Margin (%)-14.84
Net PROFIT Margin (%)-43.98
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-24.63
Total Debt / Equity (X)0.83
Asset Turnover Ratio (%)0.56

Solara Active Pharma Sciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual1,258.70
Total Current Assets Annual790.65
Non Current Assets Annual1,555.95
Total Shareholders Funds Annual937.42
Total Assets Annual2,346.60

Solara Active Pharma Sciences Ltd Earning Calls

EPS (INR)

Expected

1.99

Reported

2.41

Surprise

21.11%

Jun 2024

EPS beaten by 21.11%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 5, 2024, Solara Active Pharma Sciences Ltd has a market capitalization of 1,340.68 Cr. Value Research classifies it as a Small-Cap company.
No, Solara Active Pharma Sciences Ltd is not debt-free with a debt-to-equity ratio of 1.08.
In FY 2023 , Solara Active Pharma Sciences Ltd recorded a total revenue of approximately 1,288.92 Cr marking a significant milestone in the company's financial performance.
Solara Active Pharma Sciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.3% and 0.0% annually, respectively..
Solara Active Pharma Sciences Ltd's current PE ratio is -2.37.
Solara Active Pharma Sciences Ltd's ROCE averaged -2.8% from the FY ending March 2022 to 2024, with a median of -0.6%. It peaked at 1.8% in March 2023, reflecting strong capital efficiency over the period..
Solara Active Pharma Sciences Ltd's latest EBIT is Rs. -382.36 Cr, surpassing the average EBIT of Rs. -117.82 Cr over the 5 years..